Back to the Lab
Up to 25% OFF Selected Products for T Cell-Mediated Cytotoxicity Research
Accelerate your immunotherapy research with ready-to-use tumor cell models and supporting immune cell systems for T cell-mediated tumor killing and immune checkpoint studies.
Explore Our Research Models
AcceGen provides ready-to-use tumor killing models, currently featuring two key areas of immunotherapy research: T cell-mediated tumor killing and immune checkpoint-dependent killing. These models are designed to support immune–tumor interaction studies, therapeutic activity evaluation, and functional cytotoxicity assessment.
T Cell Killing Models
Evaluate T cell-mediated tumor killing using tumor cell models and immune cell systems for antigen-specific killing, CAR-T and TCR-T evaluation, and quantitative cytotoxicity studies.
Explore T Cell Killing Models →Checkpoint Killing Models
Evaluate immune checkpoint blockade and checkpoint-dependent tumor killing using tumor cell, reporter, and immune cell models for immunotherapy research.
Explore Checkpoint Killing Models →Designed for Immunotherapy Evaluation
Our ready-to-use cell models help researchers simplify assay setup, support reproducible experimental workflows, and evaluate functional responses to emerging immunotherapies.
Designed to support diverse experimental needs, these models provide flexible options for building relevant immune–tumor systems and evaluating therapeutic responses across different immunotherapy research workflows.
Immune–Tumor Interaction · Therapeutic Activity Evaluation · Functional Cytotoxicity Assessment · Quantitative Tumor Killing
Expanding Immunotherapy Evaluation Solutions
We are continuously expanding our tumor killing model portfolio to support emerging immunotherapy applications, including T cell therapy, NK cell therapy, checkpoint blockade, ADC development, and bispecific antibody research.
Stay tuned for new model releases, validation data, and immunotherapy research solutions.
